Complications during inpatient thrombosis prophylaxis - Experience from 40 patients with heparin-induced thrombocytopenia type II (HIT II)

被引：0
作者：
Hensel J. [1 ]
Dresing K. [1 ]
Zierott G. [1 ]
Stürmer K.M. [1 ]
机构：
[1] Klinik für Unfallchirurgie, Plastische und Wiederherstellungschirurgie, Universitätsklinik Göttingen
来源：
European Journal of Trauma | 2000年 / 26卷 / 5期
关键词：
Embolism; Heparin allergy; Heparin-induced thrombocytopenia; Thrombosis; Thrombosis prophylaxis;
D O I：
10.1007/PL00002446
中图分类号：
学科分类号：
摘要：
Heparin-induced thrombocytopenia Type II (HIT II) is based on a hypersensitivity to heparin and results in serious thromboembolic complications with a lethality of up to 23%. Due to its various manifestations - with or without thrombosis and/or a reduced number of thrombocytes-, a reliable diagnosis proves difficult and can only be made by a combination of clinical signs, thrombocytic behavior and antibody screening. From January 1993 to March 2000, 40 cases of HIT II were observed amongst a total of 25,331 patients presenting at 2 surgical clinics, one of which being specialized in emergency surgery. These patients were analyzed according to clinical and laboratory parameters, at first in retrospect and from 1995 prospectively. In 96.8%, thrombosis prophylaxis was done with unfractionated heparin (incidence of HIT II, 0.16%) and in 3.2% using low molecular weight heparin (incidence, 0%). All HIT II cases occurred following treatment with unfractionated heparin (in 40% subcutaneous, in 47.5% combined subcutaneous/intravenous, and in 12.5% intravenous administration). A positive result in the antibody (AB) tests was obtained on average on day 15.4 (10 to 27) SD ± 3.91. For AB testing, the HIPA and/or ELISA test or the agglutination test were used. Average age of the 27 female and 13 male patients was 62.8 SD ± 15.47 years (27 to 85). HIT II was diagnosed in 24 patients (60%) following an accident (group I) and in 16 patients (40%) after endoprosthetic joint replacement (group II). Group I was subdivided into patients suffering from single trauma (14 patients, 58.3%), multiple injury (6 patients, 25%) with an average ISS of 9.7 (4 to 15), and polytrauma (4 patients, 16.7%) with an average ISS of 24.4 (20 to 36). All accident patients sustained injury to at least 1 joint. A marked reduction in the number of thrombocytes was observed in 80%, a reduction < 50% in 10%. 10% showed no reduction or even an increase. Primary thromboembolic complications were clinically manifest - partly overlapping - on average on day 13.6 (11 to 21) SD ± 3.63, the complications being venous thromboses (42.5%), pulmonary emboli (35%), arterial thromboses (27.5%), and mesenteric artery thromboses (10%). Amputation was necessary in 7-5%, death occurred in 10% of the patients.
引用
收藏
页码：226 / 232
页数：6
相关论文
共 26 条
[11]  
Refludan®, USA, Lepirudin Scientific monograph
[12]  
Unerwunschte Arzneimittelwirkungen durch fraktionierte und unfraktionierte Heparine: Heparin-induzierte Thrombozytopenien - Aufklarung immunologischer Ursachen zum Schutz der Patienten, Dtsch Arztebl, 89, (1992)
[13]  
Danaparoid bei Heparin-induzierter Thrombozytopenie Typ II, Arzneimittelther Express, 41, pp. 1-4, (1998)
[14]  
Greinacher A., Mueller-Eckhardt C., Diagnostik der Heparinassoziierten Thrombozytopenie, Dtsch Med Wochenschr, 116, pp. 1479-1482, (1991)
[15]  
Amiral J., Bridey F., Dreyfus M., Vissoc A.M., Fressinaud E., Wolf M., Meyer D., Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia, Thromb Haemost, 68, pp. 95-96, (1992)
[16]  
Fratantoni J.C., Pollet R., Gralnick H.R., Heparin-induced thrombocytopenia: Confirmation of diagnosis with in vitro methods, Blood, 45, pp. 395-401, (1997)
[17]  
Warkentin T.E., The clinical picture of heparin-fnduced thrombocytopenia, Bull Intens Crit Care, 4, pp. 2-7, (1997)
[18]  
Wenzl M.E., Leffringhausen W., Scherlitzky L., Extremitatenverluste bei heparininduzierter Thrombozytopenie, Unfallchirurg, 99, pp. 607-611, (1996)
[19]  
Vun C.M., Evans S., Chong B.H., Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia, Thromb Res, 81, pp. 525-532, (1996)
[20]  
Koninger J., Greinacher A., Muller-Beissenhirtz W., Strosche H., Heparin-assoziierte Thrombozytopenie durch niedermolukulare Heparine, Unfallchirurg, 98, pp. 49-51, (1995)
123